A detailed history of Verity Asset Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Verity Asset Management, Inc. holds 30,342 shares of BMY stock, worth $1.76 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares
30,342
Previous 15,648 93.9%
Holding current value
$1.76 Million
Previous $650 Million 141.57%
% of portfolio
0.59%
Previous 0.25%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$39.66 - $51.75 $582,764 - $760,414
14,694 Added 93.9%
30,342 $1.57 Billion
Q2 2024

Aug 08, 2024

BUY
$40.25 - $52.99 $379,799 - $500,013
9,436 Added 151.9%
15,648 $650 Million
Q1 2024

May 28, 2024

BUY
$47.98 - $54.4 $15,113 - $17,136
315 Added 5.34%
6,212 $337 Million
Q4 2023

Feb 08, 2024

BUY
$48.48 - $57.85 $48,480 - $57,850
1,000 Added 20.42%
5,897 $303 Million
Q3 2023

Nov 22, 2023

SELL
$57.89 - $64.73 $52,911 - $59,163
-914 Reduced 15.73%
4,897 $284 Million
Q2 2023

Aug 15, 2023

SELL
$63.71 - $70.74 $313,644 - $348,253
-4,923 Reduced 45.86%
5,811 $372 Million
Q1 2023

May 24, 2023

BUY
$65.71 - $74.53 $355,951 - $403,729
5,417 Added 101.88%
10,734 $744 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $91,763 - $108,660
-1,340 Reduced 20.13%
5,317 $383 Million
Q3 2022

Nov 15, 2022

BUY
$0.13 - $76.84 $39 - $23,436
305 Added 4.8%
6,657 $473 Million
Q1 2022

May 23, 2022

SELL
$61.48 - $73.72 $1.78 Million - $2.13 Million
-28,920 Reduced 81.99%
6,352 $464,000
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $2.17 Million - $2.6 Million
35,272 New
35,272 $459,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Verity Asset Management, Inc. Portfolio

Follow Verity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Verity Asset Management, Inc. with notifications on news.